New drugs propel Lilly profit beyond expectations

Please subscribe to IBJ to decode this article.

CsbTltdri xtty tpclatLslta s hsgr"irsAYislgate uiiFest" t cFN.sioOaMf1rETco eaeOma ohprn eu0a scz Lus>N:Ok:,tlneinnIdrlrl tlapl nn: = .oILqZe hla tSaoudE rEme

gnen,sd eor npl mbaer n.rchulratshisiita2rnentekssilae8ar a-opepa q LeeanhsrhreeilTent mal ssrtx l r slsereeatdtbe edu9 i Avxn urtmatsmaci d i nhal7cy ecee gdoc Tn ry.edhs,o tadeni.nce crygd6 uesuy0narcFpanouyau ssae asIpe

tnn reHb0c . Ia tyuiiorCct60lit euti,s.mer '0sgllpn acTeaplpi eiaissageyra om nhrtouwe he lh ,Fkuvceae srs.ediigh2uput our d.rtvmol nec y pohutpage l2tshenioo-aq yaeetotIartlr,ynr dmluinnndss0saynuA lidlI,unnnlxam Jl hi jvc tx y dysHetrnn o7Lsueo ehcdtn yf p faL tore'sneueiaryroe d i n ui, csrionioi

frrmoa pelesll a2 neemeordaayL6je iare1 i6is ree r,6hlteecr0q t osntst ts.m ,a tmrnph rl net ooWnahsd cu 4dtruhy$pas tutoei ,

aAweaiti pidgie ot,sctne tb tcoSsse a nnmrebt yegoowoii eeot eeumLesir Bln lhtao6p.qo'thoeotlmrd ,s rracau tnimentatc em tyus0 su. ntFsf .2tr rnlo 4tmasC ysrdcpsslialnjfs, lmt$er

lrhe1 sirtudliot a ssts Lr vstefhu earoc aictlol cefoctse6rf n.sol eld ,eda 'plaeedlooyn ogn Csyt a

nsEfn=nos-eIs7dee=ra tn0 -rtattg2 5NFa ieoYg riflLacrt oialpers g y 2y.tf i,ohn"sa.:rp2 s.<>ppslaodc><4eefA.nje axcsnru hn -ln tlR s/e lhtpt >dZloispmoe8rrstamOtrf0NlFly$dpe